BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 90.87 |
| Open | 91.14 |
| Bid | 90.45 x 200 |
| Ask | 90.50 x 100 |
| Day's range | 90.02 - 91.53 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,406,075 |
| Market cap | 17.169B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 103.99 |
| EPS (TTM) | 0.87 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 109.70 |
ZacksBioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GuruFocus.comInsider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.
PR NewswireBioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.
© 2024 Yahoo. All rights reserved.